{"id":"W4389234876","doi":"10.1182/blood-2023-180107","title":"Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Oncology; Clinical endpoint; Chemotherapy regimen; Progression-free survival; Nivolumab; Randomized controlled trial; Chemotherapy; Cancer; Lymphoma; Hodgkin lymphoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001946055,0.0007008627,0.0009922837,0.0003505554,0.0002421299,0.0007642549,0.0005524463,0.0007254052,0.003793908],"category_scores_gemma":[0.001494815,0.0003017673,0.001713707,0.0002690122,0.00052419,0.0007373443,0.000308646,0.002025614,0.0004182455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001102474,"about_ca_system_score_gemma":0.0009723271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008892865,"about_ca_topic_score_gemma":0.002333744,"domain_scores_codex":[0.9995167,0.0002649896,0.00002968597,0.00007405948,0.00003938318,0.00007514386],"domain_scores_gemma":[0.9988208,0.0003550019,0.0003077784,0.00006052136,0.00004984627,0.0004059306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9313985,0.008158342,0.008732222,0.0004003674,0.0009093987,0.00005357923,0.0001009,0.002307262,0.004291722,0.0001270732,0.002039821,0.04148083],"study_design_scores_gemma":[0.2785922,0.6611591,0.0456953,0.0001425239,0.002018586,0.0003006212,0.00009855637,0.004733547,0.004012243,0.0004798117,0.00272788,0.0000396178],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956582,0.002384195,0.0001308709,0.0002345772,0.00007180009,0.0001763062,0.0006447985,0.00002214523,0.0006771807],"genre_scores_gemma":[0.9970561,0.0007838934,0.0002073,0.0001825402,0.00009661476,0.0002235619,0.0005446555,0.000008475565,0.0008968554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003793908,"threshold_uncertainty_score":0.01269186,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01525429658443943,"score_gpt":0.277822775644979,"score_spread":0.2625684790605395,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}